BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 9139553)

  • 1. Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment.
    Kaplan MM; DeLellis RA; Wolfe HJ
    Ann Intern Med; 1997 May; 126(9):682-8. PubMed ID: 9139553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of colchicine in patients with primary biliary cirrhosis poorly responsive to ursodiol and methotrexate.
    Lee YM; Kaplan MM
    Am J Gastroenterol; 2003 Jan; 98(1):205-8. PubMed ID: 12526960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methotrexate in patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid.
    Kaplan MM; Bonder A; Ruthazer R; Bonis PA
    Dig Dis Sci; 2010 Nov; 55(11):3207-17. PubMed ID: 20559727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of methotrexate, colchicine, and other immunomodulatory drugs in the treatment of primary biliary cirrhosis.
    Kaplan MM
    Semin Liver Dis; 1997 May; 17(2):129-36. PubMed ID: 9170200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methotrexate therapy for the symptomatic treatment of primary biliary cirrhosis patients, who are biochemical incomplete responders to ursodeoxycholic acid therapy.
    Babatin MA; Sanai FM; Swain MG
    Aliment Pharmacol Ther; 2006 Sep; 24(5):813-20. PubMed ID: 16918885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: ten-year results.
    Kaplan MM; Cheng S; Price LL; Bonis PA
    Hepatology; 2004 Apr; 39(4):915-23. PubMed ID: 15057894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone.
    González-Koch A; Brahm J; Antezana C; Smok G; Cumsille MA
    J Hepatol; 1997 Jul; 27(1):143-9. PubMed ID: 9252088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective trial of colchicine and methotrexate in the treatment of primary biliary cirrhosis.
    Kaplan MM; Schmid C; Provenzale D; Sharma A; Dickstein G; McKusick A
    Gastroenterology; 1999 Nov; 117(5):1173-80. PubMed ID: 10535881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary biliary cirrhosis.
    Gong Y; Christensen E; Gluud C
    N Engl J Med; 2005 Dec; 353(25):2719-20; author reply 2719-20. PubMed ID: 16379089
    [No Abstract]   [Full Text] [Related]  

  • 10. Methotrexate improves biochemical tests in patients with primary biliary cirrhosis who respond incompletely to ursodiol.
    Bonis PA; Kaplan M
    Gastroenterology; 1999 Aug; 117(2):395-9. PubMed ID: 10419921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colchicine for primary biliary cirrhosis.
    Gong Y; Gluud C
    Cochrane Database Syst Rev; 2004; (2):CD004481. PubMed ID: 15106254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of primary biliary cirrhosis with low-dose weekly methotrexate.
    Kaplan MM; Knox TA
    Gastroenterology; 1991 Nov; 101(5):1332-8. PubMed ID: 1936805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.
    Corpechot C; Abenavoli L; Rabahi N; Chrétien Y; Andréani T; Johanet C; Chazouillères O; Poupon R
    Hepatology; 2008 Sep; 48(3):871-7. PubMed ID: 18752324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
    Günsar F; Akarca US; Ersöz G; Karasu Z; Yüce G; Batur Y
    Hepatogastroenterology; 2002; 49(47):1195-200. PubMed ID: 12239904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years.
    Chan CW; Gunsar F; Feudjo M; Rigamonti C; Vlachogiannakos J; Carpenter JR; Burroughs AK
    Aliment Pharmacol Ther; 2005 Feb; 21(3):217-26. PubMed ID: 15691295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial.
    Angulo P; Dickson ER; Therneau TM; Jorgensen RA; Smith C; DeSotel CK; Lange SM; Anderson ML; Mahoney DW; Lindor KD
    J Hepatol; 1999 May; 30(5):830-5. PubMed ID: 10365809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of cirrhosis in a patient with primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
    Vallone TM; Ditelberg J; Kaplan MM
    Dig Dis Sci; 2005 Jan; 50(1):167-70. PubMed ID: 15712656
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of additional administration of colchicine in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: a prospective randomized study.
    Ikeda T; Tozuka S; Noguchi O; Kobayashi F; Sakamoto S; Marumo F; Sato C
    J Hepatol; 1996 Jan; 24(1):88-94. PubMed ID: 8834030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of primary biliary cirrhosis].
    Szalay F
    Orv Hetil; 2003 Sep; 144(36):1787-8. PubMed ID: 14579676
    [No Abstract]   [Full Text] [Related]  

  • 20. Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone.
    Rabahi N; Chrétien Y; Gaouar F; Wendum D; Serfaty L; Chazouillères O; Corpechot C; Poupon R
    Gastroenterol Clin Biol; 2010; 34(4-5):283-7. PubMed ID: 20417047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.